Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Novo Nordisk A/S
Juan P Frias; Srikanth Deenadayalan; Lars Erichsen; Filip K Knop; Ildiko Lingvay; Stanislava Macura; Chantal Mathieu; Sue D Pedersen; Melanie Davies